Persistent expression of CD26/DPPIV after treatment with infliximab in psoriasis despite clinical improvement.
van Lingen
Rosanne G
RG
van Erp
Piet E J
PE
Seyger
Marieke M B
MM
de Jong
Elke M G J
EM
de Boer-van Huizen
Roelie T
RT
Driessen
Rieke J B
RJ
van de Kerkhof
Peter C M
PC
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001706:Biopsy; D003879:Dermatologic Agents / Q000627:therapeutic use*; D018819:Dipeptidyl Peptidase 4 / Q000378:metabolism*; D005260:Female; D006801:Humans; D000069285:Infliximab; D015603:Keratinocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D012720:Severity of Illness Index; D013601:T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D003879:Dermatologic Agents; D000069285:Infliximab; C042807:DPP4 protein, human; D018819:Dipeptidyl Peptidase 4